Chronic Fatigue Syndrome Will Be First Of PDUFA V’s Disease Area Meetings
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA is bringing an ongoing program to spur drug development for CFS and myalgic encephalomyelitis under the umbrella of the user fee program’s Patient-Focused Drug Development initiative, which calls for 20 patient-centric meetings over five years.
You may also be interested in...
FDA Casts Wide Net For Patient-Focused Meeting Topics
Just a few slots remain under the agency’s original commitment under the PDUFA program, but the patient-engagement efforts appear highly valuable to FDA and industry alike.
FDA Uses AdComm Process To Shine Light On Ampligen’s Troubled Development
December’s Arthritis Advisory Committee review of Hemispherx’s drug provided FDA with the first public opportunity to explain in detail why the chronic fatigue syndrome drug, in development for almost 25 years, has not passed regulatory muster to date.
Chronic Fatigue Syndrome Drug Development Efforts Get A Boost From FDA
Agency is undertaking a series of activities with patients, advocacy groups and other stakeholders aimed at spurring development of new treatments. Hemispherx is hoping its investigational drug Ampligen, currently under FDA review, will become an early beneficiary of new statutory provisions on expedited approval.